Dermata Therapeutics Inc. Unveils Corporate Presentation Highlighting Breakthroughs in Topical Dermatology Treatments

Reuters

06/11

<a href="https://laohu8.com/S/DRMA">Dermata Therapeutics Inc</a>. Unveils Corporate Presentation Highlighting Breakthroughs in Topical Dermatology Treatments

Dermata Therapeutics Inc. has released a corporate presentation highlighting their advancements in dermatology treatments. The company showcases their unique, multi-use topical platform technology targeting the large medical and aesthetic dermatology market. Key developments include Xyngari, a once-weekly topical treatment for acne, which has shown statistically significant results in the STAR-1 Phase 3 study. A second Phase 3 study, STAR-2, is slated to begin in 2025. Additionally, Dermata's program for psoriasis has completed a positive Phase 1b study, and their DMT410 product for hyperhidrosis is planning a Phase 2a trial with DAXXIFY following a successful Phase 1 proof-of-concept with BOTOX. The presentation also outlines the market opportunities within dermatology, including a prevalence of 50 million acne cases in the US alone, and a growing demand for hyperhidrosis treatments. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief on June 10, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2542349716"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542349716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542349716?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-11 00:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542349716","market":"us","top_or_hot":-1,"title":"Dermata Therapeutics Inc. Unveils Corporate Presentation Highlighting Breakthroughs in Topical Dermatology Treatments","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DRMA\">Dermata Therapeutics Inc</a>. Unveils Corporate Presentation Highlighting Breakthroughs in Topical Dermatology Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Dermata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has released a corporate presentation highlighting their advancements in dermatology treatments. The company showcases their unique, multi-use topical platform technology targeting the large medical and aesthetic dermatology market. Key developments include Xyngari, a once-weekly topical treatment for acne, which has shown statistically significant results in the STAR-1 Phase 3 study. A second Phase 3 study, STAR-2, is slated to begin in 2025. Additionally, Dermata's program for psoriasis has completed a positive Phase 1b study, and their DMT410 product for hyperhidrosis is planning a Phase 2a trial with DAXXIFY following a successful Phase 1 proof-of-concept with BOTOX. The presentation also outlines the market opportunities within dermatology, including a prevalence of 50 million acne cases in the US alone, and a growing demand for hyperhidrosis treatments. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dermata Therapeutics Inc. Unveils Corporate Presentation Highlighting Breakthroughs in Topical Dermatology Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDermata Therapeutics Inc. Unveils Corporate Presentation Highlighting Breakthroughs in Topical Dermatology Treatments\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-11 00:51</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DRMA\">Dermata Therapeutics Inc</a>. Unveils Corporate Presentation Highlighting Breakthroughs in Topical Dermatology Treatments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Dermata <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has released a corporate presentation highlighting their advancements in dermatology treatments. The company showcases their unique, multi-use topical platform technology targeting the large medical and aesthetic dermatology market. Key developments include Xyngari, a once-weekly topical treatment for acne, which has shown statistically significant results in the STAR-1 Phase 3 study. A second Phase 3 study, STAR-2, is slated to begin in 2025. Additionally, Dermata's program for psoriasis has completed a positive Phase 1b study, and their DMT410 product for hyperhidrosis is planning a Phase 2a trial with DAXXIFY following a successful Phase 1 proof-of-concept with BOTOX. The presentation also outlines the market opportunities within dermatology, including a prevalence of 50 million acne cases in the US alone, and a growing demand for hyperhidrosis treatments. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DRMA","symbol_name":"Dermata Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDLbsMj83:1","article_id":"2542349716","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542349716","pubTimestamp":1749574291,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Dermata Therapeutics Inc. has released a corporate presentation highlighting their advancements in dermatology treatments. The company showcases their unique, multi-use topical platform technology targeting the large medical and aesthetic dermatology market. Key developments include Xyngari, a once-weekly topical treatment for acne, which has shown statistically significant results in the STAR-1 Phase 3 study. A second Phase 3 study, STAR-2, is slated to begin in 2025. Additionally, Dermata's program for psoriasis has completed a positive Phase 1b study, and their DMT410 product for hyperhidrosis is planning a Phase 2a trial with DAXXIFY following a successful Phase 1 proof-of-concept with BOTOX. The presentation also outlines the market opportunities within dermatology, including a prevalence of 50 million acne cases in the US alone, and a growing demand for hyperhidrosis treatments. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DRMA":"Dermata Therapeutics Inc","BK4539":"次新股","BK4007":"制药","BK4139":"生物科技"},"translate_title":"Dermata Therapeutics Inc.发布公司演示文稿，强调局部皮肤病治疗的突破","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRMA":0.9},"content_text":"Dermata Therapeutics Inc. Unveils Corporate Presentation Highlighting Breakthroughs in Topical Dermatology Treatments\n    \n\n        Dermata Therapeutics Inc. has released a corporate presentation highlighting their advancements in dermatology treatments. The company showcases their unique, multi-use topical platform technology targeting the large medical and aesthetic dermatology market. Key developments include Xyngari, a once-weekly topical treatment for acne, which has shown statistically significant results in the STAR-1 Phase 3 study. A second Phase 3 study, STAR-2, is slated to begin in 2025. Additionally, Dermata's program for psoriasis has completed a positive Phase 1b study, and their DMT410 product for hyperhidrosis is planning a Phase 2a trial with DAXXIFY following a successful Phase 1 proof-of-concept with BOTOX. The presentation also outlines the market opportunities within dermatology, including a prevalence of 50 million acne cases in the US alone, and a growing demand for hyperhidrosis treatments. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief on June 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}